Stratégies des grandes firmes pharmaceutiques face aux médicaments génériques (notice n° 675689)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02507cam a2200325 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121201439.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Yacoub, Nejla |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Stratégies des grandes firmes pharmaceutiques face aux médicaments génériques |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2010.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 35 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | RésuméQuelles sont les stratégies adoptées par les grandes firmes pharmaceutiques face à la concurrence mondialisée des génériques ? Dans cet article, nous nous intéressons à l’arbitrage que ces firmes réalisent entre les stratégies d’ accumulation et de valorisation de leur capital-savoir. Ce dernier est défini comme l’ensemble des informations, connaissances et savoir-faire qu’elles produisent, acquièrent, combinent et systématisent dans le but d’être utilisés dans le processus de production de valeur. Nous montrons que les grandes firmes pharmaceutiques cherchent d’abord la rentabilité à court terme, privilégiant les objectifs de valorisation de leur capital-savoir existant tandis que leurs objectifs d’accumulation du capital-savoir sont ciblés sur l’innovation mineure. Codes JEL : L12, L21, L65 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | What are the strategies adopted by Big Pharmaceutical Firms ( Big Pharma) face to the globalized generics competition? In this paper our interest is targeted on the arbitration of these firms between knowledge-capital accumulation and knowledgecapital valorisation strategies. The knowledge-capital is defined as the set of information, knowledge, know-how that a firm produces, acquires, combines and systemizes to be used in the value production process. We show that Big Pharma are short-run profit seeking, privileging the objectives of valorisation of their existent knowledge-capital while their objectives of accumulation of knowledge-capital are targeted on minor innovation. JEL codes: L12, L21, L65 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | capital-savoir |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | brevets |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | accumulation |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | médicaments génériques |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | valorisation |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | innovation |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | stratégies des firmes pharmaceutiques |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Big Pharma strategies |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | generic drugs |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | patents |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | innovation |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | knowledge-capital |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Laperche, Blandine |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations | 32 | 2 | 2010-06-17 | p. 81-107 | 1267-4982 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-innovations-2010-2-page-81?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-innovations-2010-2-page-81?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux